News · 26 weeks64+33%
2026-03-012026-08-23
Mix2190d
- SEC Filings7(33%)
- Other4(19%)
- Insider3(14%)
- Dividends3(14%)
- Analyst2(10%)
- Earnings2(10%)
Latest news
25 items- SECBaxter International Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- PRBaxter Appoints John Rogers Chief Financial OfficerGlobal medtech CFO with broad transformation and leadership experience to help advance Baxter’s turnaround, financial discipline and value creation Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed John Rogers as executive vice president and chief financial officer (CFO), reporting to Baxter president and chief executive officer (CEO), Andrew Hider, effective Oct. 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818180217/en/John Rogers, Appointed Baxter CFO "John is a proven global finance executive with extensive operational expertise and a successful track record leadi
- SECBaxter International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- PRBaxter Announces Pricing for Its Upsized Cash Tender OffersBaxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the pricing terms for its previously announced cash tender offers (each, an "Offer" and collectively, the "Offers") of the Company's validly tendered (and not validly withdrawn) notes set forth below (the "Notes") using a "waterfall" methodology under which the Company will accept the Notes in order of their respective acceptance priority levels noted in the table below (the "Acceptance Priority Levels"). The Offers are being made pursuant to an Offer to Purchase, dated Aug. 4, 2026, as amended by the Company’s press release relating to the early tender results and upsizing of the Offers issued on Aug. 18, 2026
- PRBaxter Announces Early Tender Results and Upsizing of Previously Announced Cash Tender OffersBaxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the early results of its previously announced cash tender offers (each, an "Offer" and collectively, the "Offers") for its validly tendered (and not validly withdrawn) notes set forth below (collectively, the "Notes"). The Offers are being made pursuant to an Offer to Purchase, dated Aug. 4, 2026 (as it may be amended or supplemented from time to time, the "Offer to Purchase"), which sets forth a description of the terms of the Offers. In addition, the Company has exercised its previously disclosed right to amend the terms of the Offers to increase the aggregate purchase price (excluding accrued and unpaid in
- SECSEC Form 8-K filed by Baxter International Inc.8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- SECBaxter International Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- PRBaxter Announces Cash Tender OffersBaxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has commenced cash tender offers (each, an "Offer" and collectively, the "Offers") for the maximum principal amount of validly tendered (and not validly withdrawn) notes set forth below (collectively, the "Notes"), such that the aggregate purchase price, not including accrued and unpaid interest, payable in respect of such Notes will not exceed $500 million. The terms and conditions of the Offers are being made pursuant to an Offer to Purchase, dated Aug. 4, 2026 (as it may be amended or supplemented from time to time, the "Offer to Purchase"). A summary of the Offers to purchase the Notes is outlin
- ANALYSTBaxter upgraded by Citigroup with a new price targetCitigroup upgraded Baxter from Sell to Neutral and set a new price target of $28.00
- SECSEC Form 10-Q filed by Baxter International Inc.10-Q - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- SECBaxter International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- PRBaxter Reports Second-Quarter 2026 ResultsSecond-quarter sales of $2.96 billion increased 5% on both a reported and organic basis,1, 2 reflecting growth in all segments and divisions Second-quarter U.S. GAAP3 diluted earnings per share (EPS) of $0.26; adjusted diluted EPS of $0.56 Company raises full-year 2026 financial outlook Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2026. "Our second-quarter results exceeded expectations on both the top and bottom lines, driven by both operating performance and an additional benefit from a tariff refund that was not previously contemplated in our guidance," said Andrew Hider, president and CEO. "While we’re encoura
- SECBaxter International Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- PRBaxter to Host Second-Quarter 2026 Financial Results Conference Call for InvestorsBaxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its second-quarter 2026 financial results on Thursday, July 30, 2026, at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/attendee/167756971 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter’s website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter’s permission. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere
- PRBaxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful ImpactAnnounces new targets, including Net-Zero greenhouse gas emissions (GHG) across Scope 1 and Scope 2 by 2050 and 100% renewable electricity by 2040 Introduces company’s refreshed sustainability strategy, goals and governance Formerly called the Corporate Responsibility Report, now published as the Sustainability Report Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its newly renamed 2025 Sustainability Report, highlighting the company’s progress and refreshed approach to advancing a sustainable and responsible business model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622741106/en/
- PRMediThinQ and Synovis Micro Companies Alliance, Inc. Announce Strategic Global Distribution Agreement to Redefine Microsurgery with the SHIYA 3D Visualization PlatformMulti-year exclusive agreement to expand access to next-generation 3D surgical visualization worldwideSEOUL, South Korea, June 18, 2026 /PRNewswire/ -- MediThinQ, a South Korea-based innovator in surgical visualization technologies, has entered into an exclusive multi-year distribution agreement with Synovis Micro Companies Alliance, Inc. ("Synovis MCA"), a subsidiary of Baxter International Inc. (NYSE:BAX) and trusted leader in microsurgical devices and solutions, to commercialize SHIYA, its 3D surgical visualization platform. Terms of this agreement were not disclosed.The agreement enables the global rollout of SHIYA through Synovis MCA, leveraging the company's deep-rooted expertise in mi
- INSIDERSVP, Interim CFO, CAO & Cntrlr Zielinski Anita A was granted 13,426 shares, increasing direct ownership by 29% to 59,714 units (SEC Form 4)4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
- INSIDERPresident, Adv. Surgery Wallace Steven P. covered exercise/tax liability with 153 shares, decreasing direct ownership by 0.22% to 70,128 units (SEC Form 4)4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
- INSIDERPresident, CCS Teaff James covered exercise/tax liability with 321 shares, decreasing direct ownership by 1% to 31,063 units (SEC Form 4)4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
- SECSEC Form SD filed by Baxter International Inc.SD - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- ANALYSTBaxter downgraded by Citigroup with a new price targetCitigroup downgraded Baxter from Neutral to Sell and set a new price target of $17.00
- SECSEC Form S-8 filed by Baxter International Inc.S-8 - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- SECBaxter International Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
- INSIDERDirector Wilkes David S. was granted 12,836 shares, increasing direct ownership by 53% to 37,076 units (SEC Form 4)4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
- INSIDERDirector Wendell Amy Mcbride was granted 12,836 shares, increasing direct ownership by 41% to 44,235 units (SEC Form 4)4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
BAX FAQ
7 questionsWhat does Baxter International Inc. do?
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical...Where does BAX stock trade?
Baxter International Inc. (BAX) is listed on NYSE.What sector and industry is BAX in?
Baxter International Inc. operates in the Health Care sector, Medical/Dental Instruments industry.Does BAX pay a dividend?
Yes. BAX's next ex-dividend date is 2026-08-28 with a declared cash dividend of $0.01 per share, payable 2026-10-01.What are analysts saying about BAX?
Baxter International Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Neutral with a $2800.00 price target on 2026-07-31. Recent price targets range from $1700.00 to $4200.00.What companies are similar to BAX?
Notable peers in the same industry include JNJ (Johnson & Johnson), SYK (Stryker Corporation), MDT (Medtronic plc.), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company). Compare BAX side-by-side with any of them on Quantisnow.How can I track BAX on Quantisnow?
Quantisnow aggregates Baxter International Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BAX to receive live email and push alerts on every new disclosure.